logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
EMA ScreenerEMA Screener
SMA ScreenerSMA Screener
WMA ScreenerWMA Screener
OHLC ScreenerOHLC Screener
Fibonacci ScreenerFibonacci Screener
VWAP ScreenerVWAP Screener
Pivot Point ScreenerPivot Point Screener
Overlay ScreenerOverlay Screener
Trend Indicator ScreenerTrend Indicator Screener
Volume Based Indicator ScreenerVolume Based Indicator Screener
Overbought/Sold ScreenerOverbought/Sold Screener
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Precious Metals
Gold Price TodayGold Price TodayNew
Silver Price TodaySilver Price TodayNew
Platinum Price TodayPlatinum Price TodayNew
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals

Large Cap•6,731 Employees•IPO 2024
Current Price
₹1696.00
-29.3 (-1.7%)Updated
NSE :EMCURE
BSE :544210
Sector :Pharmaceuticals
Today's Range
1675
₹1696.00
indicator
1750
52 Week Range
52W Low₹1228.90
52W High₹1830.00
₹1696.00
indicator
Downside38.01%
Upside7.90%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹27,876.64 Cr
Market Cap
Total market value of company
P/E Ratio
32.05
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
5.12
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹45.90
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
9.41%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
20.70%
ROCE
Return on Capital Employed. >15% is good
Net Margin
9.83%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
-%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
15.70%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
45.30%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.23
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹234.65
Book Value
Net asset value per share
Dividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
77.90%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •Emcure Pharmaceuticals demonstrates robust quarterly profit growth, with a significant 45.30% increase in net profit for the latest quarter, indicating strong operational performance and profitability.
  • •The company maintains a healthy balance sheet with a low debt-to-equity ratio of 0.23, suggesting prudent financial management and reduced financial risk for investors.

Weaknesses

4 points
  • •The company's current P/E ratio of 33.70 appears relatively high when compared to some established peers like Cipla (23.66) and Dr Reddy's Labs (18.07), suggesting a premium valuation.
  • •Emcure's stock has shown recent negative momentum, with a decline from 1385.00 to 1339.60 over the last five trading days, indicating short-term price volatility.

Opportunities

3 points
  • •Operating within the robust Pharmaceuticals sector, Emcure is well-positioned to capitalize on increasing global healthcare demand and emerging market opportunities for growth.
  • •Emcure's superior quarterly sales growth of 15.72% compared to many larger peers suggests potential for market share gains and outperformance in the competitive landscape.

Threats

4 points
  • •The highly competitive pharmaceuticals industry, with numerous established players like Sun Pharma and Cipla, poses a significant threat to Emcure's market share and pricing power.
  • •As a pharmaceutical company, Emcure faces inherent risks from stringent and evolving regulatory landscapes, which could impact product approvals and operational costs.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹1889.00+₹193.00+11.38%
R3₹1814.00+₹118.00+6.96%
R2₹1782.00+₹86.00+5.07%
R1₹1739.00+₹43.00+2.54%
PIVOT₹1707.0011.000.65%
CURRENT₹1696.00--
S1₹1514.00-₹182.00-10.73%
S2₹1589.00-₹107.00-6.31%
S3₹1632.00-₹64.00-3.77%
S4₹1664.00-₹32.00-1.89%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
2.30L
(29 May 2026)
-1.6% vs avg
Delivery %
60.1%
(29 May 2026)
+12.6% vs avg
Avg Volume (20D)
2.34L
(30 Apr - 29 May)
20-day average
Avg Delivery %
47.6%
(30 Apr - 29 May)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Acutaas Chemicals Ltd
93.50 %
Highest Dividend Yield
Glaxosmithkline Pharmaceuticals Ltd
3.32 %

Peer Comparison

Company Name
ACUTAAS
Acutaas Chemicals Ltd
AJANTPHARM
Ajanta Pharma Ltd
APLLTD
Alembic Pharmaceuticals Ltd
ASTRAZEN
Astrazeneca Pharma India Ltd
COHANCE
Cohance Lifesciences Ltd
ERIS
ERIS Lifesciences Ltd
GLAND
Gland Pharma Ltd
GLAXO
Glaxosmithkline Pharmaceuticals Ltd
IPCALAB
Ipca Laboratories Ltd
JBCHEPHARM
J B Chemicals & Pharmaceuticals Ltd
NEULANDLAB
Neuland Laboratories Ltd
PFIZER
Pfizer Ltd
PPLPHARMA
Piramal Pharma Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
WOCKPHARMA
Wockhardt Ltd

About

EMCURE

Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited is a global pharmaceutical company specializing in the development, manufacturing, and marketing of a wide range of pharmaceutical products. Their diverse portfolio spans numerous therapeutic areas, encompassing treatments for gynecological conditions, cardiovascular diseases, infections, HIV, respiratory illnesses, gastrointestinal disorders, pain, blood-related issues, cancer (oncology/antineoplastics), diabetes, neurological conditions, dermatological problems, and other health concerns. Additionally, they offer vitamins, minerals, and nutritional supplements, showcasing a commitment to comprehensive healthcare solutions.

Emcure's manufacturing capabilities are extensive and sophisticated. They employ diverse drug development platforms, including expertise in chiral molecules, complex active pharmaceutical ingredients (APIs), oral medications, iron-based products, photochemistry-based drugs, liposomal and lyophilized injectables, high-potency drugs, biotherapeutics, and innovative drug delivery systems. This broad technological base allows them to produce a variety of drug formulations to meet diverse market needs and patient requirements.

The company markets its products under several well-established brand names, including Orofer, Bevon, Maxtra, Zostum, Metpure, and Eslo. These brands represent the company's commitment to providing quality and effective medications across a spectrum of therapeutic areas. The use of established brand names aids in market recognition and builds consumer trust, a critical aspect of success in the competitive pharmaceutical industry.

Founded in 1981 and headquartered in Pune, India, Emcure Pharmaceuticals has a long history of innovation and growth within the pharmaceutical sector. Their continued investment in research and development across multiple therapeutic platforms, combined with their diverse manufacturing capabilities and established brand presence, positions them for continued success in the global pharmaceutical market.

COMPANY FACTS - EMCURE

Registered Address

Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi

Pune

MAHARASHTRA

IN

Tel: 912035070033

Website:https://www.emcure.com/

Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 6,731

IPO Date: 10/07/2024

MANAGEMENT - EMCURE

Mr. Berjis Desai

Non-Executive Chairman of the Board

Mr. Satish Mehta

Chief Executive Officer, Managing Director, Executive Director

Mr. Tajuddin Shaikh

Chief Financial Officer

Mr. Chetan Sharma

Company Secretary, Compliance Officer

Dr. Mukund Gurjar

Whole Time Director

Mr. Samit Mehta

Whole Time Director

Mr. Sunil Mehta

Whole Time Director

Mrs. Namita Thapar

Whole Time Director

Dr. Shailesh Ayyangar

Independent Director

Mr. Vijay Gokhale

Independent Director

Mr. Palamadai Jayakumar

Independent Director

Dr. Vidya Yeravdekar

Independent Director

Investor Questions Answered

Emcure Pharmaceuticals Ltd (EMCURE) Stock FAQs

Get answers to the most common questions about Emcure Pharmaceuticals Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Emcure Pharmaceuticals Ltd (EMCURE) is ₹1,696. Today, the stock has declined by ₹29.30 (1.70%), trading in a range of ₹1,675 to ₹1,750. The stock opened at ₹1,739.9 with a trading volume of 2,30,123 shares.
Emcure Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹27,876.64 crores, P/E ratio of 32.05, ROE of 9.41%, and ROCE of 20.70%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Emcure Pharmaceuticals Ltd (EMCURE) is ₹1,830, while the 52-week low is ₹1,228.9. Currently trading at ₹1,696, the stock is 77.7% away from its 52-week low and 7.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Emcure Pharmaceuticals Ltd stock at ₹1,696 depends on multiple factors. The stock is currently trading with a P/E ratio of 32.05 and P/B ratio of N/A. Today's performance shows a loss of 1.70%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Emcure Pharmaceuticals Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,696, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Emcure Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 32.05, P/B Ratio: N/A, ROE: 9.41%, ROCE: 20.70%, Dividend Yield: 0.00%, EPS: ₹45.90, Book Value: ₹234.65, Debt-to-Equity: 0.23, and Current Ratio: N/A. The company's market cap stands at ₹27,876.64 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Emcure Pharmaceuticals Ltd stock opened at ₹1,739.9 and is currently trading at ₹1,696, showing a decline of ₹29.30 (1.70%). The intraday high is ₹1,750 and low is ₹1,675. The trading volume stands at 2,30,123 shares, indicating moderate market participation today.
Emcure Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 32.05, which means investors are willing to pay ₹32.05 for every ₹1 of earnings. With an EPS of ₹45.90, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Emcure Pharmaceuticals Ltd has a market capitalization of ₹27,876.64 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹1,696) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Emcure Pharmaceuticals Ltd has a book value of ₹234.65 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,696, which is 622.8% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Emcure Pharmaceuticals Ltd has a Return on Equity (ROE) of 9.41% and Return on Capital Employed (ROCE) of 20.70%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Emcure Pharmaceuticals Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Emcure Pharmaceuticals Ltd has a debt-to-equity ratio of 0.23, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Emcure Pharmaceuticals Ltd has an Earnings Per Share (EPS) of ₹45.90, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,696 and P/E ratio of 32.05, investors are paying 32.05 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Emcure Pharmaceuticals Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Emcure Pharmaceuticals Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Emcure Pharmaceuticals Ltd stock, consider: 1) Fundamental Analysis - Review P/E (32.05), ROE (9.41%), debt-to-equity (0.23), and growth rates. 2) Technical Analysis - Check 52-week range (₹1228.90 - ₹1830.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1696.00) with book value (₹234.65) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Emcure Pharmaceuticals Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,696 is 16860x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Emcure Pharmaceuticals Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1228.90 - ₹1830.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.23 indicates leverage. 4) Liquidity Risk - Based on trading volume of 2,30,123 shares. 5) Valuation Risk - P/E of 32.05 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Emcure Pharmaceuticals Ltd operates in the industry with key metrics: P/E ratio of 32.05, ROE of 9.41%, market cap of ₹27,876.64 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.23), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Emcure Pharmaceuticals Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,696, with a 52-week range of ₹1228.90 to ₹1830.00. Based on fundamentals like P/E (32.05), ROE (9.41%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Emcure Pharmaceuticals Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1696.00. 2) Fundamental Deterioration - Declining ROE (currently 9.41%), increasing debt (D/E: 0.23), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Emcure Pharmaceuticals Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.

Related

Peers, sector trends, screeners and strategy playbooks contextual to this stock.